ALLYSA JONES: Open Payments
NPI 1073141875 · WESTWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$803 in 25 payments from 8 companies in 2025. Trend: 2023 $591 · 2024 $573 · 2025 $803
Food & beverage: $803
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 8 | $185 |
| AstraZeneca Pharmaceuticals LP | 4 | $184 |
| Eisai Inc. | 4 | $181 |
| ABBVIE INC. | 5 | $95 |
| GlaxoSmithKline, LLC. | 1 | $86 |
| Genmab U.S., Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: LYNPARZA, Lenvima, KEYTRUDA, ELAHERE, Tivdak, Orserdu, KISQALI.
Industry payments across KS — which companies pay providers there.
